Zealand Pharma A/S

Price Chart

Risk-Adjusted Performance

Also Listed On

Zealand Pharma A/S (ZEAL) Price Performance

Zealand Pharma A/S (ZEAL) trades on Nasdaq Copenhagen in DKK. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at DKK300.80, down 8.65% from the previous close.

Over the past year, ZEAL has traded between a low of DKK234.90 and a high of DKK545.80. The stock has lost 25.9% over this period. It is currently 44.9% below its 52-week high.

Zealand Pharma A/S has a market capitalization of $22.34B, with a price-to-earnings ratio of 3.51.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.